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Background. Mycobacterium tuberculosis remains a global health problem and clinical management is complicated by difficulty 
in discriminating between latent infection and active disease. While M.  tuberculosis-reactive antibody levels are heterogeneous, 
studies suggest that levels of IgG glycosylation differ between disease states. Here we extend this observation across antibody do-
mains and M. tuberculosis specificities to define changes with the greatest resolving power.
Methods. Capillary electrophoretic glycan analysis was performed on bulk non-antigen–specific IgG, bulk Fc domain, bulk 
Fab domain, and purified protein derivative (PPD)- and Ag85A-specific IgG from subjects with latent (n = 10) and active (n = 20) 
tuberculosis. PPD-specific isotype/subclass, PPD-specific antibody-dependent phagocytosis, cellular cytotoxicity, and natural killer 
cell activation were assessed. Discriminatory potentials of antibody features were evaluated individually and by multivariate analysis.
Results. Parallel profiling of whole, Fc, and Fab domain-specific IgG glycosylation pointed to enhanced differential glycosylation 
on the Fc domain. Differential glycosylation was observed across antigen-specific antibody populations. Multivariate modeling high-
lighted Fc domain glycan species as the top discriminatory features, with combined PPD IgG titers and Fc domain glycans providing 
the highest classification accuracy.
Conclusions. Differential glycosylation occurs preferentially on the Fc domain, providing significant discriminatory power be-
tween different states of M. tuberculosis infection and disease.
Keywords.  tuberculosis; antibodies; glycosylation; Fc effector function; diagnostics.
Tuberculosis is the leading cause of infectious disease deaths 
worldwide [1]. Current diagnostic tools are suboptimal with 
nonspecific clinical symptoms and poorly sensitive and resource-
demanding microbial-based tests such as acid-fast smears and 
culture or nucleic acid amplification. Moreover, T-cell based tu-
berculin skin tests and interferon-γ (INF-γ) release assays do not 
distinguish between individuals with latent infection who are 
clinically well and the 5%–10% of this population who progress 
to active tuberculosis disease, the primary source of transmis-
sion and mortality if untreated [2]. Thus, a simple point-of-care 
diagnostic with an enhanced ability to distinguish latent from 
active tuberculosis could dramatically limit disease [3].
Recent studies demonstrate that host immune responses as 
measured by blood inflammatory transcripts [4] and immune 
complex activity [5] correlate with latent and active tuberculosis 
[6]. However, because these measures are not microbe specific, 
utility as a biomarker for infection is uncertain. While antigen-
specific T-cell mediated immunity is critical in preventing the 
acquisition and progression of disease [7], current antigen-
specific T-cell–based tests fail to distinguish latent from active 
tuberculosis [2]. Conversely, while the role of humoral immu-
nity in the control of Mycobacterium tuberculosis is less clear 
and the overall magnitude of the antibody (Ab) response rep-
resents an unreliable biomarker [8], Ab constant (Fc) domain 
features shift with disease states, resolving latent and active tu-
berculosis [5].
Shifts in Ab glycosylation have been observed with autoim-
mune disease [9, 10], age [11], pregnancy [12], and HIV infec-
tion [13, 14]. Data from mice and also humans from 2 distinct 
geographic regions have noted Ab changes with tuberculosis 
disease severity [5, 15, 16]. Specifically, Abs in patients with ac-
tive tuberculosis are agalactosylated, similar to those with auto-
immune flares [16]. Importantly, these changes were observed 
across total circulating and antigen-specific IgG.
N-linked glycosylation on a single conserved site on the CH2 
domain of the IgG Fc is critical for downstream effector func-
tions [17]. This glycan structure consists of a core biantennary 
complex of N-acetyl glucosamine and mannose residues. This 
core is further extended with sialic acid (SA), galactose (G), 
fucose (F), and a bisecting N-acetyl glucosamine (GlcNAc) [17], 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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which in combination generate up to 36 unique glycoforms that 
may be attached to the Fc domain [17]. These changes modify 
Fc affinity for Fc receptors on immune cells, regulating a variety 
of cellular effector functions including cytotoxicity, phagocy-
tosis, antigen presentation, and inflammation [18]. Moreover, 
IgG glycosylation has been noted to diverge across antigen 
specificities within a given individual [13, 19–23], suggesting 
that Ab glycosylation may develop in an antigen-specific manner.
Beyond Fc glycosylation, approximately 20% of IgG is 
glycosylated on the antigen binding (Fab) domain, due to sto-
chastic incorporation of N-glycan sites during somatic hyper-
mutation [24, 25]. Thus, the Fab represents an additional source 
of glycan heterogeneity detected from the whole Ab. Whether 
M. tuberculosis infection-associated glycan changes occur across 
the whole Ab, or preferentially on the Fc or Fab domain, or on 
particular antigen-specific Ab subpopulations is unclear, but 
could provide further insights into biomarkers of tuberculosis 
disease state.
The aim of this study was to evaluate the potential for dif-
ferential Ab profiles to discriminate between latent and active 
tuberculosis. To begin to define the specific Ab glycan changes, 
glycosylation profiles were measured on whole, Fc, and Fab 
fragments of circulating and M. tuberculosis purified protein de-
rivative (PPD)- or Ag85A-specific IgG [26]. Alterations in bulk 
IgG glycosylation between latent and active tuberculosis largely 
correlated with Fc domain changes. Analysis incorporating all 
Ab features revealed that Fc domain glycosylation provided the 
greatest resolution of disease states, particularly when com-
bined with measures of PPD Ab titers.
METHODS
Study Population
Adult HIV-seronegative subjects with latent (n = 10) and active 
(n = 20) tuberculosis were recruited in south Texas (Hidalgo 
County Department of Health and Human Services) and 
Mexico (Secretaria de Saluld de Tamaulipas). A diagnosis of ac-
tive tuberculosis was based on M.  tuberculosis isolation from 
sputum and latent tuberculosis on a positive Quantiferon-
Gold (Qiagen) or T.Spot.TB (Oxford Immunotec) assay. Data 
on age, gender, BCG vaccination status, glycated hemoglobin 
(HbA1C), and body mass index (BMI) were collected [27] 
(Supplementary Table). All study participants gave written, in-
formed consent. The study was approved by the institutional 
review boards of the participating institutions.
Isolation of Whole Bulk IgG
Total IgG was purified from plasma using Melon Gel resin 
(ThermoScientific) and filtered through 0.2-µM (Fisher) and 
300-kDa filters (Amicon).
Isolation of Fc and Fab Domains
To cleave whole IgG into Fc and Fab domains, whole IgG 
(20 µg) was digested with IdeS (Promega) at 37°C for 1 hour. 
Fc domains were isolated with protein G beads (Millipore) at 
room temperature for 1 hour. The supernatant containing the 
Fab fragments was removed for further processing. Glycans 
were isolated from samples containing whole IgG, Fab, or Fc 
fragments and labeled using Glycan Assure APTS kit (Life 
Technologies, A28676).
Isolation of PPD- and Ag85A-specific IgG Glycans
PPD (Statens Serum Institute) or recombinant Ag85A (BEI) 
were biotinylated with sulfosuccinimidyl-6-[biotinamido]-
6-hexanamido hexanoate (sulfo-NHS-LC-LC biotin; 
ThermoScientific) and coupled to streptavidin columns 
(Agilent) through which plasma was passed, then washed with 
phosphate-buffered saline (PBS; Corning). Antigen-specific 
Abs were eluted using 100 mM citric acid (pH 3.0) and neutral-
ized with 0.5 M potassium phosphate (pH 9.0). IgG was puri-
fied from the eluted antigen-specific Abs by protein G beads. 
N-linked glycans from IgG samples were cleaved by peptide-
N-glycosidase F (NEB) [28]. Proteins were precipitated in ice-
cold ethanol. Glycan-containing supernatants were dried by 
CentriVap, labeled with a 1:1 ratio of 50 mM 8-aminoinopyrene-
1,3,6-trisulfonic acid (APTS; ThermoFisher) in 1.2 M citric acid 
and 1 M sodium cyanoborohydride in tetrahydrofuran (Sigma-
Aldrich) at 55°C for 2 hours with unbound APTS removed 
using Bio-Gel P-2 (Bio-Rad) size exclusion resin.
Analysis of Glycans
APTS-labeled samples were run with a LIZ 600 DNA ladder in 
Hi-Di formamide (ThermoFisher) on an Applied Biosystems 
3500/3500xL Genetic Analyzer and analyzed with GlycanAssure 
Data Acquisition Software v.1.0.
PPD-specific IgG Quantitation
To determine PPD-specific IgG titers, enzyme-linked immu-
nosorbent assay (ELISA) plates (Nunc) were coated with PPD 
(250 ng/mL) or PBS-5% bovine serum albumin (BSA) at 4°C 
for 16 hours and blocked with PBS-5% BSA at room tempera-
ture for 2 hours. IgG samples were incubated at room temper-
ature for 2 hours. HRP-conjugated anti-human IgG (1:500 in 
PBS; R&D Systems) was incubated at room temperature for 1 
hour. Wells were developed in 0.4 mg/mL o-phenylenediamine 
in PBS/H2O2 and stopped by 2.5 M H2SO4. Absorbances were 
measured at 450 and 570 nm.
Antigen-Specific IgG Subclass Quantitation
Relative levels of antigen-specific Ab subclasses were quanti-
fied by customized Luminex [29]. Carboxylated microspheres 
(Luminex) were coupled with PPD, Ag85A, M.  tuberculosis 
culture filtrate (BEI), and M. tuberculosis soluble protein (BEI) 
by covalent N-hydroxysuccinimide (NHS)-ester linkages via 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochlo-
ride (EDC) and NHS (ThermoScientific). Antigen-coated 
microspheres (5000/well) were added to each sample (5 µg bulk 
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IgG) in 5 replicate wells of a 96-well plate (Millipore) and in-
cubated at 4°C for 16 hours. Microspheres were washed, and 
IgG1-, IgG2-, IgG3-, IgG4-, or bulk IgG-specific detection re-
agents (Southern Biotech) were added at room temperature for 
2 hours. Beads were read on a Bio-Plex 200 System. The back-
ground signal (mean fluorescence intensity [MFI] of micro-
spheres incubated with PBS) was subtracted.
THP1 Phagocytosis Assay
PPD was biotinylated with sulfo-NHS-LC BIOTIN 
(ThermoFisher) and incubated with 1  μm fluorescent 
neutravidin beads (Invitrogen) at 4°C for 16 hours. Excess an-
tigen was washed away. Antigen-coated beads were incubated 
with IgG samples (100  µg/mL) at 37°C for 2 hours to which 
THP1 cells (1  ×  105/well) were added and incubated further 
at 37°C for 16 hours. Bead uptake in fixed samples was meas-
ured on a BD LSRII. The integrated MFI (% bead-positive fre-
quency × MFI/10 000) generated phagocytic scores [30].
Antibody-Dependent Cellular Cytotoxicity Assay
A modified rapid fluorometric antibody-dependent cellular 
cytotoxicity assay was used [31, 32]. CEM-NKr CCR5+ cells 
(National Institutes of Health AIDS Reagent Program) were 
pulsed with PPD (60 µg/mL) at room temperature for 1 hour 
and labeled with the intracellular dye 5(6)-carboxyfluorescein 
diacetate N-succinimidyl ester
 (CFSE; Sigma) and membrane dye PKH26 (Invitrogen). NK 
cells were isolated from seronegative donor whole blood with 
RosetteSep (Stem Cell Technologies). Purified IgG (100 µg/mL) 
was added to the labeled CEM-NKr cells (2 × 104/well) and in-
cubated with NK cells (2 × 105/per well) at 37°C for 4 hours. The 
proportion of PKH26+ cells lacking intracellular CFSE staining 
(% dead cells) in fixed samples was determined by flow cytometry.
Ab-Dependent NK Cell Activation
ELISA plates were coated with PPD (300  ng/well) or BSA at 
4°C for 16 hours [33]. Purified IgG (25 µg) from study parti-
cipants was added to each well. NK cells were isolated from 
whole blood from seronegative donors with RosetteSep. NK 
cells (5 ×  104/well) were incubated with anti-CD107a–phyco-
erythrin (PE)–Cy5 (BD), brefeldin A (10 mg/mL) (Sigma), and 
GolgiStop (BD) at 37°C for 5 hours. Cells were stained for sur-
face markers using anti-CD16–allophycocyanin (APC)–Cy7 
(BD), anti-CD56–PE–Cy7 (BD), and anti-CD3–AlexaFluor 
700 (BD), and then intracellularly with anti-IFN-γ–APC (BD) 
and anti-MIP1β–PE (BD) using Fix and Perm A  and B solu-
tions (ThermoFisher). Frequency (%) of NK cells positive for 
CD107a, IFN-γ, and MIP1β were determined with NK cells de-
fined as CD3− and CD16/56+.
Ab-Dependent Neutrophil Activation
Healthy donor whole blood was mixed with equal volume of 
3% dextran-500 (ThermoFisher) at room temperature for 25 
minutes to pellet red blood cells. Leukocytes were removed, 
washed in Hank's Balanced Salt Solution (HBSS) without cal-
cium and magnesium (ThermoFisher), and separated using 
Ficoll-Histopaque (Sigma-Aldrich) centrifugation. The granu-
locyte pellet was harvested. PPD-coated beads were incubated 
with IgG (100  µg/mL) at 37°C for 2 hours to which isolated 
neutrophils (1  ×  105/well) were added and incubated further 
at 37°C for 16 hours. Bead uptake by neutrophils identified by 
CD66b (BioLegend) was measured by flow cytometry.
Analysis
Statistical analysis and graphing were performed using 
GraphPad Prism 7.0, JMP Pro 12, and Matlab in a nonpara-
metric approach to avoid assumptions about data normality. 
To compare percent Ab sugar levels across whole IgG, Fc, and 
Fab domains and bulk, PPD- specific, and Ag85A-specific 
Abs within the same individual, a Friedman statistic value 
was obtained first. If the Friedman statistic value was <0.05, 
Wilcoxon matched pairs signed rank was used to evaluate the 
statistical significance between each combination of 2 groups 
within the 3. Mann-Whitney tests were used to compare per-
cent glycan levels between different individuals with latent or 
active tuberculosis. Principal component analysis was per-
formed using default parameters in JMP Pro 12.
While Fab and Fc glycosylation is thought to occur independ-
ently [24, 25], it is plausible that relationships may exist among 
particular features in polyclonal responses. Thus, we applied a 
multivariate approach to define the minimal set of Ab features 
that could separate latent and active tuberculosis. Specifically, 
this modeling utilizes prefeature downselection by the least ab-
solute shrinkage and selection operator (LASSO) [34] and visu-
alization by partial least square discriminant analysis (PLSDA) 
to ensure that as few features as possible are selected to cap-
ture the greatest variance across disease states while avoiding 
overfitting. Ab effector functions, whole, Fab, Fc, PPD-specific 
and Ag85A-specific glycans, and IgG titers were features with 4 
potential covariates: age, gender, HbA1c, and BMI. Latent and 
active tuberculosis were binary outputs. There were 30 subjects, 
each with 193 measurements. Each feature was centered 
and scaled (Z scores). Robustness was evaluated using 5-fold 
cross-validation replicates with subjects randomly divided into 
5 subsets and used exactly once in the test fold against the 4 
subsets that served as the training set. A second internal 5-fold 
cross-validation using only the training dataset determined the 
coefficient for the LASSO penalty term. A  fold-specific sup-
port vector machine [35] classifier (linear kernel with default 
Matlab parameters) was trained using LASSO-selected features 
to predict clinical outcomes. Twenty independent 5-fold cross-
validation replicates were performed, with visualizations of la-
tent variables by PLSDA on the LASSO-selected features [36]. 
The identified correlates showed the same trend even without 
data imputation.
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Model performances were measured using 2 independent 
“irrelevant datasets” with repetitions of 5-fold cross-validation 
generating a distribution of model classification accuracies: 
permuted data [37] and randomly selected size-matched fea-
tures. These irrelevant datasets generated models to establish 
a baseline against which true model performance was com-
pared. For each control model, processes were repeated 100 
times to generate a distribution of accuracies. Predicted clin-
ical outcomes were compared to true clinical outcomes to ob-
tain classification accuracy. Exact P values are tail probabilities 
of true in the distribution of control model classification ac-
curacies. Median P values across independent cross-validation 
replicates are reported.
RESULTS
Divergent Glycans on Fc and Fab Domains and Whole IgG
Previous studies pointed to differences in Ab glycosylation pro-
files between latent and active tuberculosis [5]. However, it was 
unclear whether these glycan changes reflected altered Fc or 
Fab glycosylation. Thus we sought to probe Ab domain-specific 
glycosylation in tuberculosis.
A high-throughput capillary electrophoretic approach [28] 
was employed to analyze released glycans from whole Abs and 
isolated Fc and Fab domains from plasma-derived IgG of in-
dividuals with latent and active tuberculosis. Significant dif-
ferences in galactose, fucose, bisecting-GlcNAc, and sialic acid 
were observed across whole, Fc, and Fab domains (Figure 1, 
Figure 2A, and Supplementary Figure 1) [24]. Consistent with 
previous reports [12], Fab domains possessed higher levels of 
digalactosylated (G2), bisected, and sialylated glycan moieties 
compared to Fc domains (Figure 1B). These differences were 
most observed in G2S2F, G2S2FB, and G2S1FB (Supplementary 
Figure 1). Lower relative levels of G0F were detected on the Fab 
domain compared to the whole and Fc domain (Supplementary 
Figure 1). For all glycan modifications, Fc glycans correlated 
more with whole glycan profiles compared to Fab glycan pro-
files (Figure 2B and Supplementary Figure 1B). These data high-
light the dominant contribution of the Fc in driving changes in 
blood-derived Ab glycan profiles.
Distinct Glycan Profiles Across Antigen Specificities
Beyond the Fab and Fc domains, accumulating data suggest that 
Ab glycosylation varies across antigen specificities in infections 
and following vaccination [13, 19–22]. To examine whether 
distinct Ab glycan changes occurred among different M. tuber-
culosis reactive Ab populations, glycosylation profiles were gen-
erated from PPD- [38] and Ag85A-[26] specific Abs, the latter a 
component of PPD [38] and with T-cell and Ab responses in the 
context of infection [39, 40] and vaccination [41]. Significant 
differences were observed between antigen-specific and bulk 
Ab glycan profiles (Figure 3). Each antigen-specific Ab pop-
ulation was associated with a divergent overall glycan profile 
(Figure 3B), with PPD- and Ag85A-specific Ab glycosylation 
more correlated with each other as compared to whole non-
antigen–specific Ab glycan populations (Supplementary Figure 
2). Similar to our previous observations, antigen-specific Abs 
had higher levels of digalactosylated, bisected, and disialylated 
structures [19–21] and lower levels of fucosylated moieties 
(Figure 3C) [20, 22]. Relative levels of G2S1F, G0F, G1F, G1FB, 
and G2F were lower while G2S2B, G2S2FB, G2S1, G2S1FB, and 
G0 were higher in Ag85A- and PPD-specific Ab subpopulations 
compared to non-antigen–specific Abs (Supplementary Figure 
2A). While Ag85A and PPD IgG were more similar to each 
other compared to total IgG, there were differences between the 
2 antigens, most notably in relative levels of G2S1F and G2S1FB 
(Supplementary Figure 2A). Thus, glycan profiles of antigen-
specific Ab subpopulations diverged from bulk Abs and from 
each other (Figure 3B), highlighting potential distinct regula-
tion of glycosylation across M. tuberculosis-specific Abs.
Diverging Ab Features Across Tuberculosis Disease States
To objectively define the specific Ab features corresponding 
to disease states, Ab glycosylation data were integrated with 
Ab function, isotype/subclass levels, and demographic data 
(Supplementary Table). Using purified IgG from individuals 
with latent or active tuberculosis, PPD-specific Ab-dependent 
cellular phagocytosis, neutrophil phagocytosis, cellular cyto-
toxicity, NK cell activation, and IgG1, 2, 3, and 4 levels to PPD, 
M.  tuberculosis culture filtrate, and M.  tuberculosis soluble 
protein were analyzed (Supplementary Table). A  supervised 
multivariate model incorporating 193 features, including dem-
ographic data as potential covariates that could influence Ab 
function and glycosylation, was utilized to determine the min-
imal set that could distinguish individuals with latent from ac-
tive tuberculosis. Feature downselection was performed using a 
LASSO, then classification using the LASSO-selected features, 
and visualization using PLSDA [36]. Our model discrimin-
ated between latent and active tuberculosis with a median clas-
sification accuracy  =  0.9 (Figure 4A). Of the 193 features, 5 
were sufficient to achieve separation (Figure 4B). Strikingly, 4 
of the 5 features were Ab glycan structures: the top 2 features 
were Fc domain G2S1F and G2FB, followed by Ag85A-specific 
galactosylation, and the fifth feature was the surface expres-
sion of CD107a, a marker of PPD-specific NK cell degranula-
tion (Supplementary Figures 3–7). No demographic feature was 
identified by the model such that these factors were less likely 
to represent confounding factors. These analyses highlight the 
dominant discriminatory power of Ab Fc glycosylation in re-
solving latent and active tuberculosis.
Combination of Ag-Specific Ab Titers and Fc Glycans to Discriminate 
Latent and Active Tuberculosis 
While Ab glycan changes have diagnostic potential [9, 10, 
13, 14], M.  tuberculosis-specific Ab titers alone have failed 
Latent and Active Tuberculosis • jid 2020:222 (15 december) • 2097
to discriminate between latent and active tuberculosis [8]. 
However, results suggest that Fc glycans have significant dis-
criminatory power (Figure 4B). To compare these 2 approaches 
in discriminating latent and active tuberculosis, we used 
LASSO to predict group classification, and generated median 
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Figure 1. Differential glycosylation of Fc, Fab, and whole antibody (Ab) in tuberculosis. A, Heatmap of individual glycan substructures (columns) for each individual 
(rows) shows differential modifications across whole (top), Fc (middle), and Fab domains (bottom) of IgG. B, Modifications of all glycan structures containing galactose 
(G0, agalactosylated; G1, monogalactosylated; G2, digalactosylated), fucose, bisecting N-acetyl glucosamine (GlcNAc), and sialic acid are graphed as percent of total IgG 
sugar modifications, separated by region (whole Ab, Fc only, and Fab only). Each dot represents an individual with latent (n = 10) or active (n = 20) tuberculosis. Bars repre-
sent median and interquartile range. Statistical significance was determined by Friedman statistic to evaluate for differences between 3 paired groups and, if appropriate, 
followed by Wilcoxon matched pairs signed rank to evaluate the statistical significance between each paired group. * P ≤ .05, ** P ≤ .01, *** P ≤ .001, **** P ≤ .001.
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and glycan data (Figure 4C). As expected, PPD-specific titers 
alone provided poor resolution across groups. In contrast, the 
addition of glycan data significantly increased classification ac-
curacy, with the best combination resulting in a median classi-
fication accuracy of >90% using Fc domain glycans and PPD 
titers (Figure 4C). Thus, M. tuberculosis-specific Ab titers and 
Fc glycosylation together may enhance discriminatory potential 
in biomarker development [42].
DISCUSSION
Modeling suggests that improved tuberculosis diagnostics 
could reduce morbidity and mortality as dramatically as a novel 
vaccine or optimized drug regimen [42]. A  blood-based di-
agnostic test could transform care, particularly in children or 
extrapulmonary disease where sputum production may be dif-
ficult or less helpful [2].
Altered glycosylation has been hypothesized to be related to 
immune activation inducing Abs with unique properties to re-
cruit effector functions [24]. We previously described differences 
in bulk Ab glycosylation among latent and active tuberculosis 
[5]. However, it was unclear whether these changes occurred due 
to alterations in Fab or Fc glycosylation [24] or linked to par-
ticular antigen-specific Ab populations [9, 13, 19–22]. Parallel 
analysis of whole, Fc, and Fab glycans highlighted that the major 
differences in Ab glycosylation were observed in the Fc, and not 
the Fab, domain (Figure 1 and Figure 4, and Supplementary 
Figures 3, 4, and 5). Different Ag specificities (PPD and Ag85A) 
were associated with divergent IgG glycosylation profiles (Figure 
3B and Figure 4). Multivariate modeling using all Ab features 
further supports that divergent Ab profiles in latent and active 
tuberculosis, which potentially reflect host immune states, can 
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Figure 2. Associations between Fc, Fab, and whole IgG glycans in tuberculosis. A, Representative plots generated via capillary electrophoresis of samples from individuals 
with latent (n = 10) or active (n = 20) tuberculosis are shown for glycans isolated from whole, Fab domain, and Fc domain IgG. Peaks are identified by alignment with stand-
ards and relative abundance is calculated by peak areas via GlycanAssure Data Acquisition Software v.1.0. B, Prominent peaks from the Fc and Fab domain were correlated 
by Spearman rank order to whole IgG. Rho (ρ) and P values are indicated. Abbreviations: G0, agalactosylated; G1, monogalactosylated; G2, digalactosylated.
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Figure 3. Differential glycosylation of purified protein derivative (PPD), Ag85A, and bulk non-antigen–specific antibody in tuberculosis. A, Heatmap shows modifications 
of glycan substructures (columns) for each individual (rows) for Ag85A (top) and PPD (bottom) specific IgG. B, Principal component analysis using all PPD (blue) and Ag85A 
(orange) glycan data demonstrates the nonoverlapping profiles. C, Modifications of all glycan structures containing galactose (G0, agalactosylated; G1, monogalactosylated; 
G2, digalactosylated), fucose, bisecting N-acetyl glucosamine (GlcNAc), and sialic acid are graphed as percent of total IgG sugar modifications, separated by region (whole 
Ab, PPD only, and Ag85A only). Each dot represents an individual with latent (n = 10) or active (n = 20) tuberculosis. Bars represent median and interquartile range. Statistical 
significance was determined by Friedman statistic to evaluate for differences between 3 paired groups and, if appropriate, followed by Wilcoxon matched pairs signed rank 
to evaluate the statistical significance between each paired group. * P ≤ .05, ** P ≤ .01, *** P ≤ .001, ****P ≤ .001.
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Because the Fab domain is typically highly sialylated and 
galactosylated compared to the Fc [9, 12, 28], it was unclear 
if differences in latent and active tuberculosis were associated 
with increased Fab glycosylation (Figure 1 and Supplementary 
Figure 1). We found that whole and Fc domain glycans correl-
ated closely with each other (Supplementary Figure 1), more so 
than whole and Fab domain glycans. Moreover, glycans from 
whole and Fc but not Fab domains discriminated latent from 
active tuberculosis (Figure 4B and 4C and Supplementary 
Figures 3–5). Consistent with these findings, of the 193 Ab 
features incorporated into the model, 4 of the downselected 5 
that were sufficient in discriminating latent and active tuber-
culosis included Fc or whole but not Fab Ab glycans (Figure 
4B). Intriguingly, one feature also selected was Ab-mediated 
induction of CD107a surface expression on NK cells (Figure 
4B), which is associated with activation and consistent with 
published literature linking NK cell function to latent tubercu-
losis in humans [5, 43]. Thus, while there is a relative abundance 
of sialic acid and galactose on Fab domains, Ab glycosylation 
changes associated with disease resolution occur on the Fc do-
main and appear to impact Ab functions.
Differences in Ab glycosylation were observed between non-
antigen–specific, PPD- and Ag85A-specific IgG glycan profiles 
(Figure 2 and Supplementary Figure 2). However, the resolving 
power of antigen-specific whole IgG glycans in this cohort was 
less than that of non-antigen–specific Fc domain sugar moieties 
(Figure 4C). This discrepancy may be due to the resolution of 
whole versus Fc domain antigen-specific glycosylation. While 
sample quantity in this study was insufficient for this compar-
ison, future work in this direction may provide enhanced res-
olution. In addition, the nature of the M. tuberculosis antigens 
used may contribute to the lower discriminatory capacity of 
antigen-specific IgG glycosylation. PPD reflects a breadth of 
M. tuberculosis antigens such that the complexity could obscure 
differences. In contrast, as 1 of the more than 4000 proteins 
encoded in the M.  tuberculosis genome [44], Abs reactive to 
Ag85A may not capture the extent of variation present against 
the M. tuberculosis antigen repertoire. Furthermore, BCG vac-
cination, received by 83% of the individuals (Supplementary 
Table), is likely to have induced humoral responses cross-reac-
tive to both PPD and Ag85A, altering the resolving power of 
both antigen-specific Ab responses. Additional M. tuberculosis-
specific targets, such as ESAT6 and CFP10 used in current 
T-cell based diagnostics, may provide even greater resolution. 
Future studies with expanded antigen libraries may provide a 
more concrete path to resolve latent and active tuberculosis in 
an antigen-specific manner and beyond current transcriptomic 
and proteomic based biomarker signatures [4, 45–47].
Ab glycosylation, with promise as biomarkers in autoimmu-
nity and cancer [9, 10, 48], represents a diagnostic approach that 
could complement current management tools for tuberculosis. 
Given emerging high-throughput chromatographic separation 
techniques for glycan analysis [28, 49] with the potential to 
transition into a point-of-care diagnostic [50], Fc glycosylation 
could be captured to discriminate between latent and active tu-
berculosis. Notably, M. tuberculosis in humans is clinically more 
than the classic dichotomy of latent infection and active disease. 
Within this spectrum are individuals who progress, those who 
potentially regress, and those who never progress. Fc glycans 
could begin to identify subpopulations with higher risk of pro-
gression and thus more benefit from therapy [28]. The best sep-
aration was observed when Fc glycosylation was combined with 
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Figure 4. Separation of latent and active tuberculosis by antibody features. A, LASSO and PLAS supervised model using all humoral features measured (Ab glycosylation, 
PPD-specific Fc effector functions, and PPD-specific subclass levels) and demographic data (age and body mass index) identified 5 features that could separate latent (blue 
dots) and active (red dots) tuberculosis with plot depicting separation. B, All 5 features are depicted as VIP scores. C, Violin distribution plots show median classification 
accuracies of PPD-specific Ab levels alone or in combination with whole, Fc, Fab, PPD, or Ag85A IgG glycans. Comparisons between specific groups were used to calculate 
statistical differences. Abbreviations: Ab, antibody; ATB, active tuberculosis; LASSO, least absolute shrinkage and selection operator; LTB, latent tuberculosis; LV, latent var-
iable; PLAS, partial least square discriminant analysis; PPD, purified protein derivative; TB, tuberculosis; VIP, variable importance in the projection.
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M. tuberculosis-specific Ab titers (Figure 4C). These data suggest 
that both quantitative changes in disease-specific Abs and qual-
itative changes in the inflammatory state of these Abs provide 
the greatest resolution, with Fc glycosylation profiling paving a 
path to point-of-care M. tuberculosis diagnostic development.
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